Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 128, Issue 3, Pages 386-388Publisher
WILEY
DOI: 10.1111/j.1365-2141.2004.05327.x
Keywords
venous thrombosis; cancer; factor V Leiden; prothrombin 20210A; risk factor
Categories
Funding
- NHLBI NIH HHS [T32 HL-07594] Funding Source: Medline
Ask authors/readers for more resources
Cancer patients have an increased risk of venous thrombosis (VT). The association of factor V Leiden (FVL) and the prothrombin 20210A variant with VT in cancer patients is not established. We genotyped 101 cancer patients with VT and 101 cancer patients without VT for these polymorphisms. Five cases and three controls were heterozygous for FVL, yielding an odds ratio of 1.7 (95% confidence interval (CI) 0.3-10.7). Five cases and no controls were heterozygous for prothrombin 20210A, for an odds ratio of 6.7 (95% CI 0.9-infinity). Prothrombin 20210A may be associated with VT risk among cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available